Comparative Pharmacology
Head-to-head clinical analysis: CAPTOPRIL AND HYDROCHLOROTHIAZIDE versus DYAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPTOPRIL AND HYDROCHLOROTHIAZIDE versus DYAZIDE.
CAPTOPRIL AND HYDROCHLOROTHIAZIDE vs DYAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Captopril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, resulting in vasodilation and decreased aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
Dyazide is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption; and triamterene, a potassium-sparing diuretic that blocks epithelial sodium channels in the collecting duct, reducing potassium excretion.
1 tablet (captopril 25 mg / hydrochlorothiazide 15 mg) orally once daily, titrated up to a maximum of 1 tablet (captopril 50 mg / hydrochlorothiazide 25 mg) twice daily.
1-2 capsules orally once daily; each capsule contains hydrochlorothiazide 25 mg and triamterene 50 mg.
None Documented
None Documented
Captopril: ~2 hours (prolonged to 6-8 hours in heart failure or renal impairment). Hydrochlorothiazide: 5.6-14.8 hours (mean ~9.6 hours; prolonged in renal impairment).
Triamterene: 1.5–2.5 hours; hydrochlorothiazide: 6–15 hours. Clinical dosing typically once daily.
Captopril: renal (95%), primarily as unchanged drug and disulfide metabolites. Hydrochlorothiazide: renal (≥95%) as unchanged drug via tubular secretion.
Renal: triamterene ~80% (as metabolites and parent), hydrochlorothiazide >95% unchanged.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic